MARATTO

article · The Lancet Respiratory Medicine

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial

202410 citationsOpen accessMakerere University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

US Agency for International Development and Janssen Research & Development.

Research topics

  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis
  • Diagnosis and treatment of tuberculosis

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1016/s2213-2600(24)00186-3

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.